Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.76 |
| ▸ | ATM | Q13315 | 1/20 | 0.76 |
| ▸ | MAPT | P10636 | 3/20 | 0.62 |
| ▸ | NPC1 | O15118 | 3/20 | 0.61 |
| ▸ | RAB9A | P51151 | 3/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | TP53 | P04637 | 4/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.59 |
| ▸ | CASP3 | P42574 | 1/20 | 0.59 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.59 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.59 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.59 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.58 |
| ▸ | MITF | O75030 | 1/20 | 0.57 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1567346 | 0.86 | LMNA (1.00) | LMNAATMMAPTNPC1RAB9A | |
| SCHEMBL18105004 | 0.84 | LMNA (0.62) | LMNAATMMAPTNPC1RAB9A | |
| SCHEMBL11829447 | 0.84 | MAPT (0.58) | LMNAATMMAPTNPC1RAB9A | |
| SCHEMBL8900040 | 0.82 | LMNA (0.66) | LMNAATMMAPTNPC1RAB9A | |
| SCHEMBL4611029 | 0.82 | ALDH1A1 (0.68) | LMNAMAPTNPC1RAB9AL3MBTL1 | |
| SCHEMBL10926682 | 0.81 | MAPT (0.51) | LMNAATMMAPTRAB9AALDH1A1 | |
| SCHEMBL8892261 | 0.81 | LMNA (0.64) | LMNAATMMAPTNPC1RAB9A | |
| SCHEMBL5717772 | 0.80 | LMNA (0.79) | LMNAATMMAPTNPC1RAB9A | |
| SCHEMBL17513948 | 0.79 | SIRT2 (0.65) | LMNAATMMAPTNPC1RAB9A | |
| SCHEMBL1220782 | 0.79 | SMN1; SMN2 (0.66) | LMNAATMMAPTNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3275440-B1 | NOVEL OXADIAZOLE DERIVATIVE AND PHARMACEUTICAL CONTAINING SAME | NAT CT GERIATRICS & GERONTOLOGY (JP) | 2022-05-04 | — | — | EP | disclosed |
| EP-3275440-B1 | NOVEL OXADIAZOLE DERIVATIVE AND PHARMACEUTICAL CONTAINING SAME | NAT CT GERIATRICS & GERONTOLOGY (JP) | 2022-05-04 | — | — | EP | disclosed |
| US-20180072708-A1 | NOVEL OXADIAZOLE DERIVATIVE AND PHARMACEUTICAL CONTAINING SAME | NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY (JP) | 2018-03-15 | — | — | US | disclosed |
| US-20180072708-A1 | NOVEL OXADIAZOLE DERIVATIVE AND PHARMACEUTICAL CONTAINING SAME | NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY (JP) | 2018-03-15 | — | — | US | disclosed |
| US-20180072708-A1 | NOVEL OXADIAZOLE DERIVATIVE AND PHARMACEUTICAL CONTAINING SAME | NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY (JP) | 2018-03-15 | — | — | US | disclosed |
| EP-3275440-A1 | NOVEL OXADIAZOLE DERIVATIVE AND PHARMACEUTICAL CONTAINING SAME | National Center for Geriatrics and Gerontology (JP) | 2018-01-31 | — | — | EP | disclosed |
| EP-3275440-A1 | NOVEL OXADIAZOLE DERIVATIVE AND PHARMACEUTICAL CONTAINING SAME | National Center for Geriatrics and Gerontology (JP) | 2018-01-31 | — | — | EP | disclosed |
| WO-2016153023-A1 | NOVEL OXADIAZOLE DERIVATIVE AND PHARMACEUTICAL CONTAINING SAME | 国立研究開発法人国立長寿医療研究センター | 2016-09-29 | — | — | WO | disclosed |
| EP-1423120-A4 | 2H-PHTHALAZIN-1-ONES AND METHODS FOR USE THEREOF | ICOS CORP (US) | 2005-12-28 | — | — | EP | disclosed |
| US-6924284-B2 | PARP inhibitors | ICOS CORPORATION (US) | 2005-08-02 | — | — | US | disclosed |
| CN-1568187-A | 2H-2,3-dinitrogen phenodiazine-1-ketone and using method thereof | ICOS CORP (US) | 2005-01-19 | — | — | CN | disclosed |
| EP-1423120-A1 | 2H-PHTHALAZIN-1-ONES AND METHODS FOR USE THEREOF | ICOS CORPORATION (US) | 2004-06-02 | — | — | EP | disclosed |
| US-20040087588-A1 | Parp inhibitors | ICOS CORPORATION | 2004-05-06 | — | — | US | disclosed |
| WO-2003015785-A1 | 2H-PHTHALAZIN-1-ONES AND METHODS FOR USE THEREOF | ICOS CORPORATION (US) | 2003-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087588-A1 | Parp inhibitors | PARP1, PARP2, PARP11 | LMNA 448/4885ATM 414/4885MAPT 729/4885 |
| US-20180072708-A1 | NOVEL OXADIAZOLE DERIVATIVE AND PHARMACEUTICAL CONTAINING SAME | APP, BACE1, PSEN1 | LMNA 1473/4885ATM 4330/4885MAPT 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.